Glass House Brands (GLAS) Non Operating Income (2020 - 2026)
Glass House Brands' (GLAS) quarterly Non Operating Income came in at -$402000.0 in Q1 2026, up 64.11% on a QoQ basis from -$1.1 million in Q4 2025.
Glass House Brands (GLAS) Non Operating Income (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Non Operating Income data on file, last reported at -$402000.0 in Q1 2026.
- On a quarterly basis, Non Operating Income changed N/A year-over-year to -$402000.0 in Q1 2026; TTM through Mar 2026 was -$4.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$485000.0, down 108.85% from the prior year.
- Non Operating Income for Q1 2026 stood at -$402000.0, up from -$1.1 million in the prior quarter.
- Over the last five years, Non Operating Income for GLAS reached as high as $22.9 million in Q2 2023 and fell as low as -$27.7 million in Q3 2022.
- Historically, Non Operating Income has averaged -$656662.4 across 5 years, with a median of -$761000.0 in 2025.
- Across the five-year window, Non Operating Income sank 981.11% in 2022 and surged 600.94% in 2023, its largest moves.
- Year by year, Non Operating Income stood at $4.8 million in 2022, then jumped by 374.36% to $22.9 million in 2023, then tumbled by 122.72% to -$5.2 million in 2024, then soared by 78.46% to -$1.1 million in 2025, then jumped by 64.11% to -$402000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$402000.0 in Q1 2026, -$1.1 million in Q4 2025, and -$262000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -402,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -402,000.00 |
| Dec 31, 2025 | -1.12 Mn |
| Sep 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -3.07 Mn |
| Jun 30, 2024 | -5.20 Mn |
| Jun 30, 2023 | 22.88 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | -27.70 Mn |
| Jun 30, 2022 | -4.57 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 833,000.00 |
| Sep 30, 2021 | -2.56 Mn |
| Jun 30, 2021 | 1.24 Mn |
| Mar 31, 2021 | 6.42 Mn |
| Mar 31, 2020 | 398,811.00 |